Alternative signaling pathways, such as MET amplification, may also be activated, as are other mechanisms such as HER2 amplification, PIK3CA, KRAS, BRAF, and small cell lung cancer transformation. This evidence concerns the gene ERBB2 and small cell lung carcinoma.